Results 291 to 300 of about 54,096 (328)
Anemia and blood transfusions in myelofibrosis: economic and organizational impact on Italian patients, caregivers and hospitals. [PDF]
Front OncolPalandri F +8 more
europepmc +1 more source
Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome Coexisting With JAK2-Positive Polycythemia Vera and Myelofibrosis. [PDF]
Ochsner JSaibaba J +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia
Expert Review of Hematology, 2022Introduction Myelofibrosis (MF) is a rare myeloproliferative neoplasm characterized by a complex symptom profile, cytopenias, splenomegaly, and potential for leukemic progression.
J. Mascarenhas
semanticscholar +1 more source
Pharmacotherapy of Myelofibrosis
Drugs, 2017Myelofibrosis (MF) is a myeloproliferative neoplasm that is pathologically characterized by bone marrow myeloproliferation, reticulin and collagen fibrosis, and extramedullary hematopoiesis. Constitutive activation of the Janus associated kinase (JAK)-signal transducers and activators of transcription signaling pathway with resultant elevation in pro ...
Douglas Tremblay +2 more
openaire +2 more sources
Myelofibrosis in neuroblastoma
Medical and Pediatric Oncology, 1982AbstractMyelofibrosis, a rare childhood disorder, has been reported as an associated complication of certain hematologic malignancies or as an isolated idiopathic process. In this report, we describe a patient with metastatic neuroblastoma whose initial presentation included the findings of myelofibrosis and leukoery‐throblastosis.
Elaine R. Morgan, Richard J. Labotka
openaire +3 more sources
Hypocholesterolemia in Myelofibrosis
JAMA: The Journal of the American Medical Association, 1981To the Editor.— Gilbert et al ( Blood 54(suppl):84, 1979) reported low serum cholesterol levels in 24 patients with polycythemia vera or myeloid metaplasia. We examined the records of 20 patients who had agnogenic myelofibrosis and myeloid metaplasia. There were 12 men and eight women aged 42 to 94 years (x = 70.5±14.5 SD), all without diseases known
George Spanos +2 more
openaire +3 more sources
Expert Opinion on Pharmacotherapy
Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with the persistence,
Bruzzese, Antonella +11 more
openaire +2 more sources
Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with the persistence,
Bruzzese, Antonella +11 more
openaire +2 more sources
Journal of Cutaneous Pathology, 1992
Cutaneous extramedullary hematopoiesis is rare, usually occurring in ueonates following intrauterine viral infections, hereditary spherocytosis or the twin transfusion syndrome. Only 20 cases of cutaneous extramedullary hematopoiesis have been reported in adults, all with myelofibrosis.
D M, Hoss, N S, McNutt
openaire +2 more sources
Cutaneous extramedullary hematopoiesis is rare, usually occurring in ueonates following intrauterine viral infections, hereditary spherocytosis or the twin transfusion syndrome. Only 20 cases of cutaneous extramedullary hematopoiesis have been reported in adults, all with myelofibrosis.
D M, Hoss, N S, McNutt
openaire +2 more sources